BSE Live
Nov 12, 13:35Prev. Close
925.30
Open Price
925.30
Bid Price (Qty.)
928.25 (1)
Offer Price (Qty.)
929.25 (9)
NSE Live
Nov 12, 13:35Prev. Close
925.30
Open Price
924.80
Bid Price (Qty.)
928.85 (7)
Offer Price (Qty.)
929.20 (13)
| Key Financial Ratios of Strides Pharma Science (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 5.68 | 10.71 | 74.25 | 44.73 | 13.14 | |
| Diluted EPS (Rs.) | 5.68 | 10.71 | 74.23 | 44.64 | 13.06 | |
| Cash EPS (Rs.) | 34.78 | 55.05 | 95.56 | 63.94 | 25.85 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 289.70 | 312.86 | 292.53 | 322.32 | 303.10 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 289.70 | 312.86 | 292.53 | 322.32 | 303.10 | |
| Revenue from Operations/Share (Rs.) | 307.26 | 243.26 | 317.89 | 308.14 | 320.35 | |
| PBDIT/Share (Rs.) | 63.53 | 31.62 | 54.82 | 76.99 | 56.64 | |
| PBIT/Share (Rs.) | 44.14 | 18.51 | 37.61 | 62.88 | 41.95 | |
| PBT/Share (Rs.) | 18.08 | 12.07 | 10.81 | 38.33 | 18.50 | |
| Net Profit/Share (Rs.) | 15.39 | 41.94 | 78.34 | 49.83 | 11.16 | |
| NP After MI And SOA / Share (Rs.) | 4.06 | 36.25 | 74.25 | 49.87 | 12.15 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 20.67 | 12.99 | 17.24 | 24.98 | 17.68 | |
| PBIT Margin (%) | 14.36 | 7.60 | 11.82 | 20.40 | 13.09 | |
| PBT Margin (%) | 5.88 | 4.96 | 3.40 | 12.43 | 5.77 | |
| Net Profit Margin (%) | 5.00 | 17.24 | 24.64 | 16.17 | 3.48 | |
| NP After MI And SOA Margin (%) | 1.32 | 14.90 | 23.35 | 16.18 | 3.79 | |
| Return on Networth/Equity (%) | 1.43 | 12.25 | 26.97 | 16.22 | 4.08 | |
| Return on Capital Employed (%) | 10.95 | 3.11 | 6.99 | 11.24 | 1.95 | |
| Return on Assets (%) | 0.59 | 4.06 | 9.90 | 5.50 | 1.45 | |
| Total Debt/Equity (X) | 0.73 | 1.19 | 1.01 | 1.10 | 1.25 | |
| Asset Turnover Ratio (%) | 44.73 | 27.29 | 42.41 | 33.99 | 38.38 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.93 | 1.15 | 1.31 | 1.22 | 1.86 | |
| Quick Ratio (X) | 0.62 | 0.82 | 1.02 | 0.99 | 1.53 | |
| Inventory Turnover Ratio (X) | 3.52 | 2.49 | 5.15 | 3.76 | 4.67 | |
| Dividend Payout Ratio (NP) (%) | 429.50 | 5.51 | 7.34 | 10.10 | 23.97 | |
| Dividend Payout Ratio (CP) (%) | 74.39 | 4.05 | 5.96 | 7.87 | 10.85 | |
| Earnings Retention Ratio (%) | -329.50 | 94.49 | 92.66 | 89.90 | 76.03 | |
| Cash Earnings Retention Ratio (%) | 25.61 | 95.95 | 94.04 | 92.13 | 89.15 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 2.54 | 2.09 | 1.72 | 3.07 | 2.23 | |
| Interest Coverage Ratios (Post Tax) (%) | 2.54 | 2.09 | 1.72 | 3.07 | 2.23 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 4,551.74 | 7,005.41 | 8,362.33 | 12,644.05 | 12,791.41 | |
| EV/Net Operating Revenue (X) | 1.65 | 3.22 | 2.94 | 4.59 | 4.47 | |
| EV/EBITDA (X) | 8.00 | 24.74 | 17.05 | 18.37 | 25.28 | |
| MarketCap/Net Operating Revenue (X) | 1.05 | 1.94 | 2.11 | 3.56 | 3.40 | |
| Retention Ratios (%) | -329.50 | 94.48 | 92.65 | 89.89 | 76.02 | |
| Price/BV (X) | 1.14 | 1.59 | 2.44 | 3.57 | 3.66 | |
| Price/Net Operating Revenue | 1.05 | 1.94 | 2.11 | 3.56 | 3.40 | |
| Earnings Yield | 0.01 | 0.08 | 0.11 | 0.05 | 0.01 |
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
09.09.2025
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
30.07.2025
Strides Pharma Standalone June 2025 Net Sales at Rs 498.62 crore, down 10.12% Y-o-Y
29.07.2025
Strides Pharma Consolidated June 2025 Net Sales at Rs 1,119.74 crore, up 2.96% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016